{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:00Z","timestamp":1789015680299,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Team Continuum Hematologic Malignancies Center"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T16:20:35Z","timestamp":1391444435000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment"],"prefix":"10.1016","volume":"14","author":[{"given":"Anupama","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Devabhaktuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Grossbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.01.006_bib1","series-title":"World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.clml.2014.01.006_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib3","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1470-2045(03)01319-6","article-title":"Part 1: Hodgkin's lymphoma \u2013 molecular biology of Hodgkin and Reed-Sternberg cells","volume":"5","author":"Thomas","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib6","unstructured":"DeVita VT, Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. Devita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. New York, NY: Lippincot Williams & Wilkins; 2011."},{"key":"10.1016\/j.clml.2014.01.006_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000478-198404000-00002","article-title":"Differential diagnostic features of nodular L\u00a0&\u00a0H Hodgkin's disease, including progressive transformation of germinal centers","volume":"8","author":"Burns","year":"1984","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2014.01.006_bib8","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","article-title":"Nodular lymphocyte-predominant Hodgkin's lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte predominant hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma","volume":"102","author":"Boudova","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0165-5876(02)00176-3","article-title":"Progressive transformation of germinal centers: review of histopathologic and clinical features","volume":"65","author":"Hicks","year":"2002","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.clml.2014.01.006_bib10","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.94.17.9337","article-title":"Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells","volume":"94","author":"Braeuninger","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2014.01.006_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199708143370703","article-title":"Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells","volume":"337","author":"Marafioti","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.01.006_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199708143370704","article-title":"Clonality in nodular lymphocyte-predominant Hodgkin's disease","volume":"337","author":"Ohno","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.01.006_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2005-10-3949","article-title":"Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma","volume":"108","author":"Liso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2003-05-1487","article-title":"Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease","volume":"103","author":"Marafioti","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistological and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2014.01.006_bib16","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib17","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0","article-title":"Patterns for presentation of Hodgkin disease. Implications for etiology and pathogenesis","volume":"71","author":"Mauch","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte-predominant Hodgkin's disease. A clinical study of 50 cases","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib19","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib20","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogov\u00e1","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X","article-title":"Hodgkin's disease, lymphocyte-predominance nodular. Increased risk of subsequent non-Hodgkin's lymphomas","volume":"51","author":"Miettinen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00390466","article-title":"Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular)","volume":"108","author":"Hansmann","year":"1984","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin's disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2014.01.006_bib24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long term outcome after radiotherapy alone for lymphocyte predominant Hodgkin's lymphoma: a retrospective multicenter study of the Australian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early stage, lymphocyte predominant Hodgkin's lymphoma: patient outcomes form a large, single institution series with long follow up","volume":"28","author":"Chen","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib26","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib27","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib28","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited stage nodular lymphocyte predominant hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib29","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib30","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage I A nodular lymphocyte predominant Hodgkin lymphoma: a report from German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib31","article-title":"Front line therapy of nodular lymphocyte predomiant Hodgkin lymphoma with rituximab. The Stanford University experience","author":"Advani","year":"2011","journal-title":"ASH Annual Meeting"},{"key":"10.1016\/j.clml.2014.01.006_bib32","article-title":"Outcome of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP","author":"Fanale","year":"2010","journal-title":"ASH Annual Meeting"},{"key":"10.1016\/j.clml.2014.01.006_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte predominant Hodgkin's lymphoma: long-term results of a phase 2 trial by the German Hodgkin Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib34","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD 20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase II trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.006_bib36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte predominant Hodgkin lymphoma","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2014.01.006_bib37","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdq063","article-title":"Lymphocyte-predominant Hodgkin lymphoma\u2013clinical features and treatment outcomes from a 30-year experience","volume":"21","author":"Jackson","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.01.006_bib38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/1042819031000149421","article-title":"Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group","volume":"45","author":"Huang","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.01.006_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.006_bib40","article-title":"Diffuse large B cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: incidence, risk factors and outcomes after a forty year experience from a single institution","author":"Sirop","year":"2012","journal-title":"ASH Annual Meeting"},{"key":"10.1016\/j.clml.2014.01.006_bib41","article-title":"The outcome of advanced stage nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) compared to classical Hodgkin Lymphoma (CHL): a matched pair analysis","author":"Xing","year":"2012","journal-title":"ASH Annual Meeting"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:02Z","timestamp":1761870302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265014000226"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}